Skip to main content

Day: May 10, 2022

REMINDER — Boralex will release its 2022 First quarter financial results on May 11

MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or “the Corporation”) announces that the release of the 2022 First quarter results will take place on Wednesday, May 11, 2022, at 9 a.m. Financial analysts and investors are invited to attend a conference call during which the financial results will be presented. Date and timeWednesday, May 11, 2022, at 9 a.m. EST To attend the conferenceDial-in numbers: 1-855-453-5257 or 409-330-8829, with access code 2263317Webcast link: https://edge.media-server.com/mmc/p/cpphdg3w Media and other interested individuals are invited to listen to the conference and view a presentation which will be broadcasted live and on a deferred basis on Boralex’s website at www.boralex.com. A full replay will also be available on Boralex’s website until May 11, 2023. The financial information...

Continue reading

REMINDER — Boralex to Hold Virtual Annual Meeting of Shareholders on May 11, 2022

MONTRÉAL, May 10, 2022 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) announces that it will hold its Annual Meeting of Shareholders in a virtual-only format at 11:00 a.m. on Wednesday, May 11, 2022. The Annual Meeting will be broadcast online in audio only. Simultaneous interpretation will also be available for English-speaking participants. The online access to the event will start at 10:30 a.m. EDT. Shareholders will not be able to attend the meeting in person. Registered shareholders and duly appointed proxyholders will be able to attend the meeting, ask questions and vote, all in real time, if they are connected to the Internet and fulfill the conditions set out in the Management Information Circular. Non-registered shareholders (shareholders who hold their Boralex shares through a securities broker,...

Continue reading

SPO Global Inc. Issues Letter to Shareholders

Shandong, China, May 10, 2022 (GLOBE NEWSWIRE) — SPO Global Inc. (OTC PINK: SPOM), a healthcare and biotech company, today provides a corporate update and letter from CEO Fengyou Lu. Dear Shareholders, We are excited to announce that from 2020 to 2021, our company launched a new sales business of low frequency therapeutic instruments and intelligent Chinese medicine decocting machines which attributed to an increase in revenues of $15,969,073. Our machines are patented in China and our clients who use and have purchased these machines include Chinese medical clinics, facilities, traditional Chinese medicine hospitals in Shandong. In total, approximately one hundred medical institutions have purchased our machines. As part of our new sales business, we have welcomed fifteen new employees to our team, who serve as sales managers...

Continue reading

TINGO and MICT Announce Execution of Definitive Merger Agreement

Merger Would Create an over $900 Million Annual Revenue and Highly Profitable Nasdaq-listed Fintech and Agri-Fintech Company Serving the African and Asian Markets Combined Company Would Have a Portfolio of Best-in–Class Financial Platforms, Products and Services With a Global Expansion Strategy  NEW YORK, NY and MONTVALE, NJ, May 10, 2022 (GLOBE NEWSWIRE) — Tingo, Inc. (OTC Markets: TMNA) (“Tingo”) and MICT, Inc. (NASDAQ: MICT) (“MICT”) announced that they have executed a definitive agreement to merge and consolidate their operations (the “Merger”) to create an over $900 million annual revenue and highly profitable Nasdaq-listed Fintech and Agri-Fintech company serving the African and Asian markets with a global expansion strategy. The Merger represents a substantial move by both Tingo and MICT to globalize their businesses...

Continue reading

CIP Real Estate Doubled Commercial Property Holdings with North Dallas Acquisition

Company plans to sell properties in Texas, California and South Carolina IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) — CIP Real Estate acquired over 2.5 million square feet of commercial real estate in Texas and Georgia late last year, effectively doubling the size of its commercial property portfolio in the U.S. In 2022, several of the company’s new North Dallas assets will be available for sale, along with select properties in California and South Carolina. “We are excited about the acquisition of the Dallas North portfolio. It fits perfectly into our value-added business plan as we implement the sales of the smaller office assets while increasing income in the industrial portfolio” said Robert Strom, Chairman of CIP Real Estate. The largest acquisition in CIP Real Estate’s history was the Dallas North Portfolio, which includes...

Continue reading

Alchip Technology Set Record Net Income and Earnings Per Share

Maintains 2022 Revenue Guidance2022 Q1 Revenue Mix by Process Nodes Leading edge process technologies, defined as those between 7nm and 12nm, accounted for 60% of Alchip’s first quarter revenue. Advanced process technologies also accounted for 60 percent of the Company’s 2021 revenue.Taipei, Taiwan, May 10, 2022 (GLOBE NEWSWIRE) — Alchip Technologies’ first quarter 2022 financial results set a quarterly net income record, while establishing two first-time marks for geographic revenue distribution and contributions to revenue by leading edge technologies.   First quarter 2022 net income set a record of $16 million, exceeding 2021 first quarter net income of $13.7 million by 17.2 percent. and fourth quarter 2021 net income of $12.7 million by 26.1 percent.   Revenue for the first quarter of 2022 reached $93.5 million, up 4.7...

Continue reading

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update. First Quarter and Recent Corporate HighlightsAnnounced that an independent data monitoring committee (DMC) has completed its planned futility/efficacy assessment of the company’s pivotal Phase 2b study of iopofosine in Waldenstrom’s macroglobulinemia (WM) and unanimously recommended continuation of the trial as planned. The DMC is an independent committee of clinical research experts charged with the review of data from the company’s ongoing pivotal trial. The DMC assessment...

Continue reading

Hudson Global Reports 2022 First Quarter Results

OLD GREENWICH, Conn., May 10, 2022 (GLOBE NEWSWIRE) — Hudson Global, Inc. (Nasdaq: HSON) (“Hudson Global” or “the Company”), a leading global total talent solutions company, announced today financial results for the first quarter ended March 31, 2022. 2022 First Quarter SummaryRevenue of $51.9 million increased 50.7% from the first quarter of 2021 and 58.0% in constant currency. Adjusted net revenue of $25.6 million increased 101.1% from the first quarter of 2021 and 107.1% in constant currency. Net income increased to $3.0 million, or $0.97 per diluted share, compared to net loss of $0.2 million, or $0.07 per diluted share, for the first quarter of 2021. Adjusted net income per diluted share (non-GAAP measure)* was $1.23 compared to $0.07 in the first quarter of 2021. Adjusted EBITDA (non-GAAP measure)* was $5.2 million compared...

Continue reading

Exela Technologies, Inc. Reports Preliminary First Quarter 2022 Results

Revenue of $279.4 million, a decline of 6.9% from Q1 2021 Loss per Share of $0.17 in the first quarter of 2022 Net loss of $57 million in the first quarter of 2022 $78 million of TCV(1) won, a 131% increase compared to Q1 2021 Small-and-Medium-Sized Business (“SMB”) continues strong growth in the first quarter of 2022 with DMR(2) customers growing 39% over Q4 2021 and DrySign users growing 200% over Q4 2021 Total debt(3) reduction of $36 million; annual interest savings of $10 million anticipated Raised $119 million through sale of common stock for business reinvestment Liquidity of $71 million as of March 31, 2022Conference call scheduled for May 10, 2022 at 11:30 AM ET IRVING, Texas, May 10, 2022 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ: XELA), a global business process automation (“BPA”)...

Continue reading

Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights

Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR “New Drugs on the Horizon” Session NXP900 Preclinical Potency Against Various Types of Cancer Cells of Squamous Origin Presented at the 2022 AACR Meeting Completed Initial Public Offering Raising $16 Million in Gross Proceeds FORT LEE, N.J., May 10, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2022 and provided an update on recent business progress. “At Nuvectis, our goal is to become a leading biopharmaceutical company by developing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.